Inhibition of human immunodeficiency virus type-1 by cdk inhibitors

Table 1 Screening of various cdk inhibitors and related molecules in HIV-1 infected cells

Selectivity	Name		ACH2	J1.1	OM10.1	U1	CEM	Jurkat	U937
			Infected				Uninfected
High	Alsterpaullone	(10 μM)	11	25	15	37	89	92	88
	Indirubin-3'-monoxime	(10 μM)	22	32	35	38	84	83	87
	Indirubin-3'-monoxime-5'-indo	(10 μM)	24	35	37	52	80	82	80
	Purvalanol A	(10 μM)	27	53	48	54	78	79	77
	r-Roscovitine	(10 μM)	32	40	30	35	75	85	82
Moderate	CGP 74514A	(10 μM)	42	56	54	52	72	77	70
	Aloisine A	(10 μM)	50	52	59	53	72	70	68
	Bohemine	(10 μM)	58	65	67	50	72	80	50
	2,6-Diaminopurine	(10 μM)	64	75	77	74	75	68	65
	2,6-Dichloropurine	(10 μM)	75	74	76	75	69	71	71
	Flavone	(10 μM)	86	85	83	85	75	67	50
Poor	6-Benzyloxypurine	(10 μM)	90	91	92	88	68	72	54
	Compound 52	(10 μM)	95	97	94	95	97	97	98
	9-Cyanopaullone	(10 μM)	97	97	95	98	95	96	97
	6-Dimethylaminopurine	(10 μM)	95	95	96	97	97	95	96
	Indirubin-3'-monoxime-5'-sulphonic acid	(10 μM)	95	95	96	96	96	96	95
	Iso-olomoucine	(10 μM)	96	96	96	97	95	95	97
	N-6-(Δ2-Isopentenyl)-adenine	(10 μM)	96	96	98	99	95	98	96
	Kenpaullone	(10 μM)	94	97	95	95	95	95	95
	Olomoucine	(10 μM)	95	95	96	96	95	95	95
	Olomoucine N9-isoppropyl	(10 μM)	96	95	95	96	95	96	96
	s-Roscovitine	(10 μM)	95	95	95	94	95	98	96
	WHI-P180	(10 μM)	95	97	98	99	98	97	98
	SC-514	(10 μM)	95	98	99	99	98	96	99

ISSN: 1742-6405